Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
Benjamin J. Chen, Dashnamoorthy Ravi, Pallavi Galera, et al.
Oncotarget (2019) Vol. 10, Iss. 21, pp. 2030-2040
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li
PubMed (2020) Vol. 10, Iss. 3, pp. 727-742
Closed Access | Times Cited: 1350
Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports
Souhel Najjar, Amanda Najjar, Derek J. Chong, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 264
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
An‐Ping Shi, Xiyang Tang, Yanlu Xiong, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 124
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Letong Cai, Yuchen Li, Jiaxiong Tan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 119
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Gang Chen, Dong-Chen Sun, Yi Ba, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 2
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
Quentin Lecocq, Marleen Keyaerts, Nick Devoogdt, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 75-75
Open Access | Times Cited: 115
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Matias Autio, Suvi‐Katri Leivonen, Oscar Brück, et al.
Haematologica (2020) Vol. 106, Iss. 3, pp. 718-729
Open Access | Times Cited: 111
Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer
Zhe Gong, Jieyun Zhang, Weijian Guo
Cancer Medicine (2020) Vol. 9, Iss. 23, pp. 9052-9063
Open Access | Times Cited: 104
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane, Soi Cheng Law, Clare Gould, et al.
Blood Advances (2020) Vol. 4, Iss. 7, pp. 1367-1377
Open Access | Times Cited: 82
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
Ewan A. Langan, Victoria Graetz, Judith Allerheiligen, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 1, pp. e55-e65
Closed Access | Times Cited: 74
Progress of immune checkpoint LAG‑3 in immunotherapy (Review)
Chanchan Shan, Xing Li, Jian Zhang
Oncology Letters (2020) Vol. 20, Iss. 5, pp. 1-1
Open Access | Times Cited: 51
Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines
Nastaran Hashemzadeh, Mitra Dolatkhah, Khosro Adibkia, et al.
Life Sciences (2021) Vol. 271, pp. 119110-119110
Closed Access | Times Cited: 49
TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation
Kui Zang, Liangliang Hui, Min Wang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 43
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol, Juliana C. Santos, Miranda Fernández-Serrano, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 214-214
Open Access | Times Cited: 42
Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma
Anthony Colombo, Monirath Hav, Mohan Singh, et al.
Blood Advances (2022) Vol. 6, Iss. 16, pp. 4675-4690
Open Access | Times Cited: 31
Novel immune checkpoint targets: A promising therapy for cancer treatments
Mohsina Patwekar, Nouroz Sehar, Faheem Patwekar, et al.
International Immunopharmacology (2023) Vol. 126, pp. 111186-111186
Closed Access | Times Cited: 20
Anticancer effect of propranolol on diethylnitrosamine‐induced hepatocellular carcinoma rat model
Yomna M. Tamim, Ahmed Nagy, Ahmed M. Abdellah, et al.
Fundamental and Clinical Pharmacology (2024) Vol. 38, Iss. 4, pp. 742-757
Closed Access | Times Cited: 7
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
Layal El Halabi, Julien Adam, Pauline Gravelle, et al.
Clinical Lymphoma Myeloma & Leukemia (2020) Vol. 21, Iss. 4, pp. 257-266.e3
Open Access | Times Cited: 48
Imaging immunity in patients with cancer using positron emission tomography
Fiona Hegi‐Johnson, Stacey E. Rudd, Rodney J. Hicks, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 25
The future of immunotherapy for diffuse large B‐cell lymphoma
Johannes Duell, Jason R. Westin
International Journal of Cancer (2024) Vol. 156, Iss. 2, pp. 251-261
Open Access | Times Cited: 5
Immune-Checkpoint Blockade Therapy in Lymphoma
Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5456-5456
Open Access | Times Cited: 34
The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling
Mélissa Alame, Emmanuel Cornillot, Valère Cacheux, et al.
Theranostics (2021) Vol. 11, Iss. 8, pp. 3565-3579
Open Access | Times Cited: 28
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
Joo Y. Song, Mary Nwangwu, Ting-Fang He, et al.
Haematologica (2023) Vol. 108, Iss. 8, pp. 2167-2177
Open Access | Times Cited: 12
The Role of the Tumor Microenvironment in T-Cell Redirecting Therapies of Large B-Cell Lymphoma: Lessons Learned from CAR-T to Bispecific Antibodies
Kirill V. Lepik, Vladislav V. Markelov
Cancers (2025) Vol. 17, Iss. 2, pp. 317-317
Open Access
The Tumor Microenvironment of DLBCL in the Computational Era
Giuseppina Opinto, Maria Carmela Vegliante, Antonio Negri, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top